Table 1 Clinical and demographics characteristics of patients with pCR, stratified by adjuvant chemotherapy in the FUSCC
Variables | No chemo (56) | chemotherapy (115) | p value |
|---|---|---|---|
Gender | |||
Female | 27(48.2) | 37(32.2%) | 0.62 |
Male | 29(51.8) | 78(67.8) | |
Age, years | 57.6 ± 11 | 54.5 ± 10.8 | 0.085 |
Clinical T stage | 0.145 | ||
T2 | 28(50.0) | 71(61.7) | |
T3/4 | 28(50.0) | 44(38.3) | |
Clinical N sage | 0.724 | ||
N0 | 17(30.4) | 38(33.0) | |
N1–2 | 39(69.6) | 77(67.0) | |
Clinical TNM staging | 0.724 | ||
II | 17(30.4) | 38(33.0) | |
III | 39(69.6) | 77(67.0) | |
CRM | 0.296 | ||
Negative | 33(58.9) | 58(50.4) | |
Positive | 23(41.1) | 57(49.6) | |
EMVI | 0.823 | ||
Negative | 39(69.6) | 82(71.3) | |
Positive | 17(30.4) | 33(28.7) | |
Operation | 0.058 | ||
AR | 25(44.6) | 69(60.0) | |
APR | 31(55.4) | 46(40.0) | |
Lymph node examined | 0.844 | ||
Median | 10 | 9 | |
Adjuvant chemotherapy regimen | |||
Cape | – | 53 | |
CapeOX | 62 | ||